Cytokine Bioscience is developing HAS2021, an investigational biological medicinal product for intra-articular administration to manage osteoarthritis symptoms. This product utilizes a patent-pending technology to preserve bioactive compounds from human amniotic membrane, aiming to reduce pain and inflammation for improved joint function.
Funding
Funding not disclosed
Founders
Product
Problem
Osteoarthritis (OA) is a prevalent degenerative arthropathy affecting a significant portion of the European population, often leading to chronic pain and reduced joint function. Current treatment paradigms include surgical interventions like total joint replacement, which carry risks of implant rejection and immune complications, alongside high societal costs.
Solution
Cytokine Bioscience is developing HAS2021, an investigational biological medicinal product designed for intra-articular administration to manage osteoarthritis symptoms. This product leverages a novel, patent-pending technology to preserve the bioactive compounds found in human amniotic membrane. HAS2021 aims to provide a non-surgical treatment option that reduces pain, inflammation, and promotes joint function. The product is formulated as lyophilized amniotic membrane powder, intended to be suspended in saline for injection.
Target Audience
The primary target audience includes orthopedic specialists, rheumatologists, and healthcare providers involved in the management of osteoarthritis.
Features
- Investigational biological medicinal product for osteoarthritis symptom management.
- Active substance derived from human amniotic membrane, processed using a patent-pending technology to maximize bioactive compound preservation.
- Formulated as 40 mg of lyophilized amniotic membrane powder per dose.
- Administered via intra-articular injection, suspended in 0.9% NaCl.
- Exhibits analgetic and anti-inflammatory effects.
- Represents a novel biological approach to osteoarthritis treatment.